Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)

D.R. Gandara; M. Kowanetz; T.S.K. Mok; A. Rittmeyer; L. Fehrenbacher; D. Fabrizio; G. Otto; C. Malboeuf; D. Lieber; S.M. Paul; L. Amler; T. Riehl; E. Schleifman; C.A. Cummings; P.S. Hegde; W. Zou; A. Sandler; M. Ballinger; D.S. Shames

Journal ArticleOPEN ACCESS

Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)

Gandara D
Kowanetz M
Mok T
et al.

Annals of Oncology (2017) 28 v460

DOI: 10.1093/annonc/mdx380

N/ACitations

71Readers

Abstract

Methods: The biomarker evaluable population (BEP) included 211 pts in POPLAR (ITT=287) and 583 pts in OAK (excludes pts with known EGFR/ALK mutations; ITT=850), with blood samples available for targeted genomic sequencing. The bTMB assay interrogates single nucleotide variants (SNVs) in 394 genes from cell-free DNA in plasma and reports a score based on the number of high-confidence SNVs identified. The BEP was grouped by bTMB cut points based on the minimum number of SNVs present.

Cite

CITATION STYLE

APA

Gandara, D. R., Kowanetz, M., Mok, T. S. K., Rittmeyer, A., Fehrenbacher, L., Fabrizio, D., … Shames, D. S. (2017). Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK). Annals of Oncology, 28, v460. https://doi.org/10.1093/annonc/mdx380

Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)

Abstract

Cite

Register to see more suggestions